MET and neoplasm: Cabozantinib is a multiple receptor tyrosine kinase inhibitor targeting MET (c‐MET), VEGFR2, RET, AXL, KIT and TIE‐2, which are implicated in tumor growth, metastasis and angiogenesis.6